Asymptomatic hyperuricaemia (n=25) | Gout (n=33) | |
---|---|---|
Age, years | 64 (13) | 61 (15) |
Male sex, n (%) | 22 (88%) | 28 (85%) |
Ethnicity, n (%) | 18 European | 21 European |
3 Asian | 17 Pacific | |
2 Māori | 4 Māori | |
2 Pacific | 1 Asian | |
Gout disease duration, years | NA | 11 (10) |
Gout flare frequency in the preceding 3 months | NA | 1.8 (4.0) |
Chronic kidney disease | 5 (20%) | 19 (58%) |
Ischaemic heart disease | 6 (24%) | 9 (27%) |
Heart failure | 4 (16%) | 10 (30%) |
Diuretic use, n (%) | 12 (48%) | 14 (42%) |
Urate-lowering therapy*, n (%) | 0 (0%) | 27 (82%) |
Duration of urate-lowering therapy, months | NA | 34 (27) |
BMI, kg/m2 | 32.0 (5.7) | 35.0 (8.3) |
Serum urate | 590 (60) µmol/L | 430 (12) µmol/L |
9.8 (1.0) mg/dL | 7.2 (2.0) mg/dL | |
Serum creatinine, µmol/L | 98 (23) | 144 (131) |
Unless specified, data are presented as mean (SD).
*Includes allopurinol and probenecid.
BMI, body mass index.